CASPER: Cardiovascular Assessment of Pediatric Cancer Survivors

• Sponsor: Istanbul University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05939089
• Collaborator: (none)
• Enrollment: 54
• Location: 1
• Actual Duration (Months): 5.7
• Patients Per Site Per Month: 9.6

Study Details

Study Description

Brief Summary

The goal of this observational study is to evaluate cardiac and vascular health status of pediatric cancer survivors.

Condition or Disease	Intervention/Treatment	Phase
Left Ventricular Dysfunction; Heart Failure	Diagnostic Test: ECG, Echocardiography, cTnI, NT-ProBNP

Detailed Description

All pediatric cancer survivors were evaluated with cardiological examination, ECG, transthoracic echocardiography (transesophageal echocardiography when required), NT-proBNP, cTnI, kidney function tests, liver function tests, fasting blood glucose, cholesterol panel, iron, iron binding capacity, ferritin, transferrin saturation, B12, vitamin D, folic acid, urinanalysis, hemogram and a questionnaire about living with heart failure.

Study Design

• Study Type: Observational
• Actual Enrollment: 54 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: Cardiovascular Assessment of Pediatric Cancer Survivors: Understanding Long-Term Effects and Risks
• Actual Study Start Date: Jan 1, 2023
• Actual Primary Completion Date: Jun 15, 2023
• Actual Study Completion Date: Jun 22, 2023

Outcome Measures

Primary Outcome Measures

1. Rate of LV Dysfunction [From the first visit at cardio-oncology division through study completion, an average of 2 years]

   Echocardiographic evaluation of left ventricular functions

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Diagnosed cancer at pediatric age

Exclusion Criteria:

• Having cancer after 18 years of age

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Istanbul Faculty of Medicine	Fatih	Istanbul	Turkey	34093

Sponsors and Collaborators

• Istanbul University

Investigators

• Principal Investigator: Cafer Zorkun, MD PhD, Faculty member

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Cafer Zorkun, Head, Division of CardioOncology, Istanbul University
• ClinicalTrials.gov Identifier: NCT05939089
• Other Study ID Numbers: COEXIST-2
• First Posted: Jul 11, 2023
• Last Update Posted: Jul 11, 2023
• Last Verified: Jul 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Cafer Zorkun, Head, Division of CardioOncology, Istanbul University: Childhood Cancer Survivors; Cardiotoxicity; cancer treatment related heart diseases
• Additional relevant MeSH terms: Ventricular Dysfunction; Ventricular Dysfunction, Left

Study Results

No Results Posted as of Jul 11, 2023